Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms
New York, USA, July 15, 2025 (GLOBE NEWSWIRE) -- Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight
Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth.
DelveInsight's 'Endometrial Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometrial cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometrial cancer pipeline domain.
Key Takeaways from the Endometrial Cancer Pipeline Report
DelveInsight's endometrial cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline endometrial cancer drugs.
Key endometrial cancer companies such as Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imvax, and others are evaluating new endometrial cancer drugs to improve the treatment landscape.
Promising pipeline endometrial cancer therapies, such as Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others, are in different phases of endometrial cancer clinical trials.
In June 2025, Daiichi Sankyo announced the first patient had been dosed in the DESTINY-Endometrial01 clinical trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer.
In May 2025, Kaida BioPharma announced it had entered into a manufacturing agreement with Northway Biotech, Inc., an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), for the manufacturing of lead product candidate, KAD101.KAD101, a novel biologic prolactin receptor antagonist, is being initially developed for the treatment of platinum-resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine, and breast cancers.
In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed.
In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) announced that the first patient has been dosed in its Phase II combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel. The trial is the most advanced of its kind to investigate a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism in patients with endometrial cancer.
In February 2025, Acrivon Therapeutics announced that the FDA had granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer.
In December 2024, Repare Therapeutics Inc. reported positive data from its MYTHIC Phase I gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase II dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
In December 2024, IDEAYA Biosciences, Inc. announced that it has dosed the first patient in the IDEAYA-sponsored Phase I trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS).
Request a sample and discover the recent advances in endometrial cancer drugs @ Endometrial Cancer Pipeline Report
The endometrial cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometrial cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometrial cancer clinical trial landscape.
Endometrial Cancer Overview
Endometrial cancer, which arises from the uterus's inner lining (the endometrium), is the most common gynecologic cancer in developed countries, with its occurrence steadily increasing. This rise is linked to factors like aging populations and growing obesity rates. Most diagnoses occur in postmenopausal women, with abnormal uterine bleeding being the most frequent symptom. Because this symptom often prompts early medical evaluation, many cases are detected at an initial stage, improving treatment success.
Several risk factors play a role in the development of endometrial cancer. Obesity, metabolic syndrome, and diabetes are key contributors, with obesity responsible for about 40% of cases. Reproductive history, such as early onset of menstruation, delayed menopause, never having given birth, and infertility, also raises risk. Genetic factors, especially Lynch syndrome, increase susceptibility. In contrast, combined oral contraceptives have been linked to a decreased risk.
Diagnosis usually involves an endometrial biopsy, often following a transvaginal ultrasound to measure endometrial thickness. However, research suggests transvaginal ultrasound can produce false-negative results, particularly in Black women, indicating that biopsy remains the definitive diagnostic method. Surgical staging, based on the International Federation of Gynecology and Obstetrics (FIGO) criteria, is essential for assessing disease extent and planning treatment.
Treatment varies by stage. Early-stage disease is generally treated with a total hysterectomy and removal of both ovaries and fallopian tubes. Additional therapies such as radiation or chemotherapy may be recommended depending on risk factors. For advanced or recurrent disease, newer treatments like immunotherapy show promise. In particular, the combination of dostarlimab (JEMPERLI) with chemotherapy has improved survival in advanced or recurrent cases. Research continues to evolve to optimize these treatment approaches and improve patient outcomes.Find out more about endometrial cancer drugs @ Endometrial Cancer Treatment
A snapshot of the Pipeline Endometrial Cancer Drugs mentioned in the report:
Drugs
Company
Phase
MoA
RoA
Selinexor
Karyopharm Therapeutics
III
Exportin 1 protein inhibitors
Oral
EG-007
Evergreen Therapeutics
III
Epidermal growth factor receptor antagonists
Injectable
Abemaciclib
Eli Lilly and Company
II
Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
Oral
Envafolimab
Alphamab Oncology/Ascletis/3D Medicine
II
Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
Subcutaneous
Sirexatamab (DKN-01)
Leap Therapeutics
II
DKK1 protein inhibitors
Intravenous
NP137
NETRIS Pharma
II
Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
Intravenous
COM 701
Compugen
I/II
Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants
Intravenous
XMT-1660
Mersana Therapeutics
I
Tubulin inhibitors
Intravenous
Learn more about the emerging endometrial cancer therapies @ Endometrial Cancer Clinical Trials
Endometrial Cancer Therapeutics Assessment
The endometrial cancer pipeline report proffers an integral view of the emerging endometrial cancer therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Endometrial Cancer Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
Therapeutics Assessment By Mechanism of Action: Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists
Key Endometrial Cancer Companies: Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others.
Key Endometrial Cancer Pipeline Therapies: Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others.
Dive deep into rich insights for new endometrial cancer treatments, visit @ Endometrial Cancer Drugs
Table of Contents
1.
Endometrial Cancer Pipeline Report Introduction
2.
Endometrial Cancer Pipeline Report Executive Summary
3.
Endometrial Cancer Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
Endometrial Cancer Clinical Trial Therapeutics
6.
Endometrial Cancer Pipeline: Late-Stage Products (Pre-registration)
7.
Endometrial Cancer Pipeline: Late-Stage Products (Phase III)
8.
Endometrial Cancer Pipeline: Mid-Stage Products (Phase II)
9.
Endometrial Cancer Pipeline: Early-Stage Products (Phase I)
10.
Endometrial Cancer Pipeline Therapeutics Assessment
11.
Inactive Products in the Endometrial Cancer Pipeline
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Key Companies
14.
Key Products in the Endometrial Cancer Pipeline
15.
Unmet Needs
16.
Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
For further information on the endometrial cancer pipeline therapeutics, reach out @ Endometrial Cancer Therapeutics
Related Reports
Endometrial Cancer Epidemiology Forecast
Endometrial Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometrial cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Endometrial Cancer Market
Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including GlaxoSmithKline, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Incyte Corporation, among others.
Advanced Endometrial Cancer Pipeline
Advanced Endometrial Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced endometrial cancer companies, including Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech, Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics, Inc., Celon Pharma SA, Dragonfly Therapeutics, among others.
Endometriosis Pipeline
Endometriosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others.
Endometriosis Pain Market
Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
Endometriosis Pain Pipeline
Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of Gilead's Livdelzi (seladelpar) and Ipsen's Iqirvo (elafibranor). These additions to the therapeutic arsenal represent meaningful progress in disease management. However, new data from Spherix Global Insights' Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis 2025 (US) reveal that pruritus—a persistent and often debilitating symptom—continues to pose a significant unmet need for many patients living with PBC. Among the 104 US gastroenterologists surveyed in the study, there was near-universal agreement on the importance of addressing pruritus—one of the most burdensome and distressing symptoms associated with PBC. Respondents estimated that approximately half of their PBC patients suffer from moderate to severe pruritus, a manifestation that significantly impacts quality of life and remains challenging to manage. As one specialist poignantly noted, 'Patients with cholestatic liver disease will go to the world's end to escape from pruritus and the insomnia it causes.' Most gastroenterologists surveyed also acknowledged a substantial unmet need for therapies specifically targeting PBC-associated pruritus. While Livdelzi has demonstrated a significant reduction in itch symptoms after six months of treatment, only about half of respondents reported that their patients on Livdelzi required no additional intervention for pruritus. The need for effective symptom control is even more pronounced among patients receiving Iqirvo, further highlighting the gap in adequate pruritus management and the continued demand for novel therapeutic approaches. In June, GSK announced that the FDA had accepted the New Drug Application (NDA) for its ileal bile acid transporter (IBAT) inhibitor, linerixibat, for the treatment of cholestatic pruritus in patients with PBC. The PDUFA target action date is set for March 24, 2026. Awareness of the IBAT class is already high among gastroenterologists, and most report they are likely to incorporate linerixibat into their treatment armamentarium if approved. As one specialist expressed, 'The results seem promising with a significant symptom reduction among moderate to severe pruritus. However, abdominal pain and diarrhea side effects are somewhat concerning and may limit real-world use.' Another echoed the sentiment, noting, 'It significantly improved symptoms of pruritus along with quality of life, which can be a challenging and quite debilitating symptom to treat.' If approved, linerixibat could represent a meaningful advancement for patients struggling with PBC-related pruritus—a symptom that continues to profoundly impair quality of life and remains inadequately addressed by current therapies. Spherix Global Insights will continue to closely track emerging developments across the PBC treatment landscape and pipeline through its Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis service. Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Jim Hickey, Gastroenterology Franchise Head Spherix Global Insights 4848794284 in to access your portfolio
Business Upturn
an hour ago
- Business Upturn
GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) — The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of Gilead's Livdelzi (seladelpar) and Ipsen's Iqirvo (elafibranor). These additions to the therapeutic arsenal represent meaningful progress in disease management. However, new data from Spherix Global Insights' Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis 2025 (US) reveal that pruritus—a persistent and often debilitating symptom—continues to pose a significant unmet need for many patients living with PBC. Among the 104 US gastroenterologists surveyed in the study, there was near-universal agreement on the importance of addressing pruritus—one of the most burdensome and distressing symptoms associated with PBC. Respondents estimated that approximately half of their PBC patients suffer from moderate to severe pruritus, a manifestation that significantly impacts quality of life and remains challenging to manage. As one specialist poignantly noted, 'Patients with cholestatic liver disease will go to the world's end to escape from pruritus and the insomnia it causes.' Most gastroenterologists surveyed also acknowledged a substantial unmet need for therapies specifically targeting PBC-associated pruritus. While Livdelzi has demonstrated a significant reduction in itch symptoms after six months of treatment, only about half of respondents reported that their patients on Livdelzi required no additional intervention for pruritus. The need for effective symptom control is even more pronounced among patients receiving Iqirvo, further highlighting the gap in adequate pruritus management and the continued demand for novel therapeutic approaches. In June, GSK announced that the FDA had accepted the New Drug Application (NDA) for its ileal bile acid transporter (IBAT) inhibitor, linerixibat, for the treatment of cholestatic pruritus in patients with PBC. The PDUFA target action date is set for March 24, 2026. Awareness of the IBAT class is already high among gastroenterologists, and most report they are likely to incorporate linerixibat into their treatment armamentarium if approved. As one specialist expressed, 'The results seem promising with a significant symptom reduction among moderate to severe pruritus. However, abdominal pain and diarrhea side effects are somewhat concerning and may limit real-world use.' Another echoed the sentiment, noting, 'It significantly improved symptoms of pruritus along with quality of life, which can be a challenging and quite debilitating symptom to treat.' If approved, linerixibat could represent a meaningful advancement for patients struggling with PBC-related pruritus—a symptom that continues to profoundly impair quality of life and remains inadequately addressed by current therapies. Spherix Global Insights will continue to closely track emerging developments across the PBC treatment landscape and pipeline through its Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis service. Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
an hour ago
- Business Upturn
Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers
By GlobeNewswire Published on July 17, 2025, 22:00 IST New York, USA, July 17, 2025 (GLOBE NEWSWIRE) — Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight Dementia associated with Alzheimer's disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population worldwide is leading to a rising prevalence of Alzheimer's-related dementia, fueling demand for effective diagnostics and disease-modifying therapies. DelveInsight's 'Dementia Associated with Alzheimer's Disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline dementia associated with Alzheimer's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the dementia associated with Alzheimer's disease pipeline domain. Key Takeaways from the Dementia Associated with Alzheimer's Disease Pipeline Report DelveInsight's dementia associated with Alzheimer's disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline dementia associated with Alzheimer's disease drugs. active players working to develop pipeline dementia associated with Alzheimer's disease drugs. Key dementia associated with Alzheimer's disease companies such as BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. , Merry Life Biomedical Company , Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. Promising pipeline dementia associated with Alzheimer's disease therapies, such as Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. In May 2025, Nuravax Inc. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. In February 2025, NKGen Biotech, Inc . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. In April 2025, Biogen announced that the US Food and Drug Administration had granted Fast Track designation to BIIB080 , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. announced that the US Food and Drug Administration had granted Fast Track designation to , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. In March 2025, Longeveron Inc. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. In February 2025, Neuphoria Therapeutics announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. In February 2025, NKGen Biotech announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of troculeucel , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. In January 2025, the US FDA granted Fast Track designation to Posdinemab , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. the US FDA granted Fast Track designation to , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. In November 2024 , Alector announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). , announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). In October 2024, Hoth Therapeutics, Inc. announced the granting of a US patent for its pioneering Alzheimer's treatment, HT-ALZ. Request a sample and discover the recent advances in dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Pipeline Report The dementia associated with Alzheimer's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage dementia associated with Alzheimer's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the dementia associated with Alzheimer's disease clinical trial landscape. Dementia Associated with Alzheimer's Disease Overview Dementia is a broad term that refers to a marked decline in cognitive abilities that affects a person's daily functioning. Alzheimer's disease (AD) is the most common form of dementia, responsible for at least two-thirds of cases in people aged 65 and older. AD is a progressive neurodegenerative disorder that begins gradually and leads to worsening impairments in behavior and cognitive skills such as memory, understanding, language, attention, reasoning, and judgment. Although Alzheimer's itself is not directly fatal, it greatly increases the risk of other complications that can ultimately result in death. The diagnosis of Alzheimer's-related dementia usually requires a thorough evaluation, including medical history, cognitive assessments, physical and neurological exams, and sometimes brain imaging. Physicians first exclude other possible causes of cognitive decline, like vitamin deficiencies or thyroid issues. Cognitive tests evaluate memory, problem-solving, and language to identify patterns indicative of Alzheimer's. Brain scans, such as MRI or CT, help detect structural changes like brain shrinkage. More advanced diagnostic tools, including PET scans or cerebrospinal fluid tests, can reveal specific biomarkers linked to Alzheimer's, offering stronger confirmation. Currently, there is no cure for Alzheimer's disease since brain cell loss cannot be reversed. However, treatments are available to ease symptoms and enhance the quality of life for patients and their caregivers. Cholinesterase inhibitors are medications that help reduce cognitive symptoms such as memory problems, confusion, and impaired judgment by improving communication between brain cells and slowing symptom progression. The three FDA-approved drugs commonly used for Alzheimer's treatment include donepezil (Aricept) for all stages, and galantamine (Razadyne) and rivastigmine (Exelon) for mild to moderate stages. Find out more about dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Treatment A snapshot of the Pipeline Dementia Associated with Alzheimer's Disease Drugs mentioned in the report: Drugs Company Phase MoA RoA Bezisterim (NE3107) BioVie III NF-kappa B inhibitor; Tumour necrosis factor inhibitor Oral KarXT Bristol Myers Squibb III Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists Oral Buntanetap Annovis Bio III Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors Oral AR1001 AriBio III Type 5 cyclic nucleotide phosphodiesterase inhibitors Oral CT-1812 Cognition Therapeutics II Sigma-2 receptor antagonists Oral TW001 Treeway B.V. II Antioxidants; Free radical scavengers Oral AMX0035 Amylyx Pharmaceuticals II Ammonia scavenger; Histone deacetylase inhibitor; Phosphotransferase inhibitor Oral CM383 KeyMed Biosciences I Amyloid beta-protein inhibitors Intravenous Learn more about the emerging dementia associated with Alzheimer's disease therapies @ Dementia Associated with Alzheimer's Disease Clinical Trials Dementia Associated with Alzheimer's Disease Therapeutics Assessment The dementia associated with Alzheimer's disease pipeline report proffers an integral view of the emerging dementia associated with Alzheimer's disease therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Dementia Associated with Alzheimer's Disease Pipeline Report Coverage : Global : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors Key Dementia Associated with Alzheimer's Disease Companies : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. Key Dementia Associated with Alzheimer's Disease Pipeline Therapies: Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others. Dive deep into rich insights for new dementia associated with Alzheimer's disease treatments, visit @ Dementia Associated with Alzheimer's Disease Drugs Table of Contents 1. Dementia Associated with Alzheimer's Disease Pipeline Report Introduction 2. Dementia Associated with Alzheimer's Disease Pipeline Report Executive Summary 3. Dementia Associated with Alzheimer's Disease Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Dementia Associated with Alzheimer's Disease Clinical Trial Therapeutics 6. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Pre-registration) 7. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Phase III) 8. Dementia Associated with Alzheimer's Disease Pipeline: Mid-Stage Products (Phase II) 9. Dementia Associated with Alzheimer's Disease Pipeline: Early-Stage Products (Phase I) 10. Dementia Associated with Alzheimer's Disease Pipeline Therapeutics Assessment 11. Inactive Products in the Dementia Associated with Alzheimer's Disease Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Dementia Associated with Alzheimer's Disease Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the dementia associated with Alzheimer's disease pipeline therapeutics, reach out @ Dementia Associated with Alzheimer's Disease Therapeutics Related Reports Alzheimer's Disease Epidemiology Alzheimer's Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted Alzheimer's disease epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including BioVie, AB Science, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, among others. Agitation in Alzheimer's Disease Market Agitation in Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key agitation in Alzheimer's disease companies, including Eli Lilly and Co, BioVie Inc., AB Science SA, Annovis Bio Inc., Cognition Therapeutics Inc., Coya Therapeutics Inc., Actinogen Medical Limited, AC Immune SA, Biogen Inc., Longeveron Inc., among others. Psychosis in Parkinson's and Alzheimer's Disease Market Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others. Alzheimer's Disease Diagnostic Market Alzheimer's Disease Diagnostic Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Alzheimer's disease diagnostic companies, including F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN™, FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
